original ) (raw )A Comparative Study of Piperacillin-Tazobactam With and Without Vancomycin as Empirical Therapy for Febrile Neutropenic Patients With Solid Tumor Malignancies
Mahmoud Shorman
World Journal of Oncology, 2015
View PDFchevron_right
Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer
A. Cometta , Marianne Paesmans
Antimicrobial Agents and Chemotherapy, 1995
View PDFchevron_right
Clinical experience with single agent and combination regimens in the management of infection in the febrile neutropenic patient
Coleman Rotstein , Reuben Ramphal
The American Journal of Medicine, 1996
View PDFchevron_right
Piperacillin-Tazobactam plus Amikacin versus Ceftazidime plus Amikacin as Empiric Therapy for Fever in Granulocytopenic Patients with Cancer
A. Cometta
2000
View PDFchevron_right
Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: a randomized prospective study
Reuben Ramphal
Antimicrobial Agents and Chemotherapy, 1992
View PDFchevron_right
Daptomycin Pharmacokinetics in Adult Oncology Patients with Neutropenic Fever
Joseph Bubalo
Antimicrobial Agents and Chemotherapy, 2009
View PDFchevron_right
Effects of teicoplanin and those of vancomycin in initial empirical antibiotic regimen for febrile, neutropenic patients with hematologic malignancies. Gimema Infection Program
Francesco Menichetti
Antimicrobial Agents and Chemotherapy, 1994
View PDFchevron_right
Oral Antibiotics for Fever in Low-Risk Neutropenic Patients With Cancer: A Double-Blind, Randomized, Multicenter Trial Comparing Single Daily Moxifloxacin With Twice Daily Ciprofloxacin Plus Amoxicillin/Clavulanic Acid Combination Therapy--EORTC Infectious Diseases Group Trial XV
Lubos Drgona
Journal of Clinical Oncology, 2013
View PDFchevron_right
Piperacillin/tazobactam/amikacin versus piperacillin/amikacin/teicoplanin in the empirical treatment of neutropenic patients
Marcio Nucci
European Journal of Clinical Microbiology & Infectious Diseases, 1993
View PDFchevron_right
Ceftazidime plus amikacin plus teicoplanin or vancomycin in the empirical antibiotic therapy in febrile neutropenic cancer patients
Irene Biasoli
Oncology Reports, 1998
View PDFchevron_right
Evaluation of an empiric antibiotic regimen in pediatric oncology patients presenting with fever does not reveal the emergence of antibiotic resistance over a 12-year period
Hossein Salimnia
Pediatric Hematology Oncology Journal, 2020
View PDFchevron_right
Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology Clinical Practice Guideline.
Mate Hidvegi
View PDFchevron_right
Piperacillin-tazobactam Versus Carbapenem Therapy With and Without Amikacin as Empirical Treatment of Febrile Neutropenia in Cancer Patients: Results of an Open Randomized Trial at a University Hospital
Hakan ÇELEBİ
Japanese Journal of Clinical Oncology, 2010
View PDFchevron_right
A Randomized, Open-Label, Multicenter Comparative Study of the Efficacy and Safety of Piperacillin-Tazobactam and Cefepime for the Empirical Treatment of Febrile Neutropenic Episodes in Patients with Hematologic Malignancies
John Seymour
Clinical Infectious Diseases, 2006
View PDFchevron_right
Monotherapy with piperacillin/tazobactam versus cefepime as empirical therapy for febrile neutropenia in pediatric cancer patients: a randomized comparison
Professor Kian Rey
Pediatric Hematology- …, 2006
View PDFchevron_right
Single-drug versus combination empirical therapy for gram-negative bacillary infections in febrile cancer patients with and without granulocytopenia
Hjalmar Lagast
Antimicrobial Agents and Chemotherapy, 1984
View PDFchevron_right
A Double-Blind Comparison of Empirical Oral and Intravenous Antibiotic Therapy for Low-Risk Febrile Patients with Neutropenia during Cancer Chemotherapy
Thomas Walsh
New England Journal of Medicine, 1999
View PDFchevron_right
Daptomycin vs. glycopeptides in the treatment of febrile neutropenia: results of the Izmir matched cohort study
Funda Yetkin
Infection, 2018
View PDFchevron_right
Low-dose β-lactam plus amikacin in febrile neutropenia: cefepime vs. piperacillin/tazobactam, a randomized trial
Salvador Quintana
European Journal of Clinical Microbiology & Infectious Diseases, 2010
View PDFchevron_right
Evaluating Initial Empiric Therapy for Neutropenic Fever in Vancomycin-Resistant Enterococcus-Colonized Patients
Yanina Pasikhova
Cancer Control, 2021
View PDFchevron_right
Piperacillin-tazobactam monotherapy in high-risk febrile and neutropenic cancer patients
A. Cometta
Clinical Microbiology and Infection, 2006
View PDFchevron_right
Randomized comparison between antibiotics alone and antibiotics plus granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived) in cancer patients with fever and neutropenia
Catherine Legrand
The American Journal of Medicine, 1996
View PDFchevron_right
Interventional antimicrobial therapy in febrile neutropenic patients
Peter Meyer
Annals of Hematology, 1994
View PDFchevron_right
Piperacillin–Tazobactum Plus Amikacin Versus Ceftazidime Plus Amikacin as Empirical Therapy for Fever in Neutropenic Patients with Hematological Malignancies
Gaurav Dixit
Indian Journal of Hematology and Blood Transfusion
View PDFchevron_right
Comparison of meropenem with amikacin plus ceftazidime in the empirical treatment of febrile neutropenia: a prospective randomised multicentre trial in patients without previous prophylactic antibiotics
V. Korten , Serhat Unal
International Journal of Antimicrobial Agents, 1999
View PDFchevron_right
A Prospective, Randomized Multicenter Trial of the Empirical Addition of Antifungal Therapy for Febrile Neutropenic Cancer Patients: Results of the Paul Ehrlich Society for Chemotherapy (PEG) Multicenter Trial II
Hartmut Link
Infection, 2006
View PDFchevron_right